A Phase 2, Multicenter, Two-Part, Open-Label Study of Pexidartinib in Adult Subjects With Tenosynovial Giant Cell Tumor in Japan
Latest Information Update: 19 Feb 2024
At a glance
- Drugs Pexidartinib (Primary)
- Indications Giant cell tumour of tendon sheath
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 11 Jul 2023 Planned End Date changed from 30 Jun 2024 to 30 Nov 2026.
- 11 Jul 2023 Planned primary completion date changed from 31 Mar 2023 to 28 Feb 2025.
- 09 Apr 2021 Status changed from not yet recruiting to recruiting, according to a Daiichi Sankyo Company media release.